SEC Tracker
Get the app

Veradermics MANE

Veradermics announces positive trial results for VDPHL01

Item 7.01 Investor disclosure, Item 8.01 Other events

Form
8-K
Filed
Importance
Notable
  1. Phase 3 trial met all primary and secondary endpoints with high statistical significance.
  2. VDPHL01 showed 28.6 hairs/cm and 36.4 hairs/cm increase in non-vellus TAHC for QD and BID arms.
  3. No treatment-related serious adverse events or cardiac-related adverse events observed.
  4. 78.8% of QD and 85.0% of BID patients reported improved hair coverage on AAIRS.

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Veradermics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. America Great Health AAGH
  2. AbbVie ABBV public float $325.1B, Jun 30, 2025
  3. Abeona Therapeutics ABEO public float $273M, Jun 30, 2025
  4. Abbott Laboratories ABT public float $232.2B, Jun 30, 2025
  5. Arbutus Biopharma ABUS public float $472M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.